Objectives: The objective of this study was to characterize a novel IMP-type metallo-b-lactamase (MBL) found in an MDR clinical isolate of Pseudomonas aeruginosa.
Introduction
Acquired Ambler class B metallo-b-lactamases (MBLs) are increasingly found in MDR Gram-negative bacteria, 1 -3 conferring resistance to almost all b-lactam antibiotics except monobactams. 4 In Pseudomonas aeruginosa, the most prevalent MBLs belong to the VIM or IMP-type, but other types, such as NDM, AIM, GIM, FIM and SPM, have also been sporadically reported. 2, 5, 6 In Germany, VIM and IMP are the most commonly found MBLs in P. aeruginosa.
7 IMP-type enzymes were the first acquired MBLs that were described and are mostly found in the south-east Asian regions but are increasingly reported in other regions worldwide. In Europe, only a few IMP-type enzymes have been reported from the UK, Italy, Portugal, France, Austria, Belgium, Poland, Romania, the Czech Republic and Slovakia. 5,8 -11 A new IMP variant has recently been reported in the Dutch -German border area. 12 To date, 50 IMP-type variants have been assigned (http://www.lahey.org/studies/). The amino acid sequences of these variants differ from each other by 1 -53 amino acid residues, which makes IMP-type enzymes a highly heterogeneous group of carbapenemases. 5 Nearly all bla IMP genes are integrated as gene cassettes into class I integrons, which usually carry additional resistance genes. 3, 5 They are encoded on plasmids or the chromosome and are often part of larger transposon structures. 5, 13 Here, we describe a new IMP-type carbapenemase found in an ST235 P. aeruginosa clinical isolate.
Materials and methods
The study was performed at Ruhr-University Bochum.
Bacterial isolate and phenotypic testing
The carbapenem-resistant P. aeruginosa isolate NRZ-00156 was recovered in 2010 from an inguinal swab from a patient hospitalized in Western Germany. It showed high MICs of carbapenems and the isolate was referred to the German National Reference Laboratory for MDR Gram-negative bacteria for further analysis. The MICs of various antibiotics were determined by Etest (bioMérieux, Nü rtingen, Germany). MBL production was detected using Etest MBL Imipenem (bioMérieux) and an EDTA combined disc test (EDTA-CDT), which was performed as previously described.
14 An EDTA bioassay based on cell-free extracts was performed as already described. 15 
PCR assays and DNA sequencing
Whole-cell DNA of the isolate was used as the PCR template. PCRs were performed for genes encoding VIM, IMP, NDM, GIM, SIM, SPM, AIM, DIM and KHM. Integron structures were analysed by amplifying the sequences between the conserved 5 ′ -CS and 3 ′ -CS regions of class I integrons. PCR products were purified using the NucleoSpin w Gel and PCR Clean-up kit (Macherey-Nagel, Dü ren, Germany) and then sequenced. Recombinant plasmids based on the pBK-CMV vector were purified using the NucleoSpin w Plasmid kit (Macherey-Nagel) and sequenced. Genome walking was performed using the Universal GenomeWalker w 2.0 Kit (Clontech, Saint-Germain-en-Laye, France) following the manufacturer's instructions. Promoter structures were analysed in silico following the classification previously described. 16 The oprD gene of P. aeruginosa NRZ-00156 was amplified, sequenced and analysed as previously described. 17 
MLST
The ST of the P. aeruginosa isolate NRZ-00156 was determined following the instructions of Curran et al. 18 Fragments of seven housekeeping genes (acsA, aroE, guaA, mutL, nuoD, ppsA and trpE) were amplified and sequenced. The STof the isolate was identified using the sequence definition tool from the P. aeruginosa MLST web site (http://pubmlst.org/paeruginosa/). eBURST analysis using eBURST software (http://eburst.mlst.net/) was performed to determine the clonal complex to which the isolate belonged.
Amino acid sequence analysis and phylogenetics
Secondary structures of IMP-31 were predicted using SWISS-MODEL. 19 The amino acid sequence of IMP-31 was aligned with 41 publicly available amino acid sequences of IMP-type MBLs retrieved from GenBank (http:// www.ncbi.nlm.nih.gov/genbank/) after removal of the signal peptide sequences. Signal peptides were predicted using the SignalP 4.0 server. 20 The amino acid sequences were aligned using ClustalW. The phylogenetic tree was constructed using the neighbour-joining method with 1000-times bootstrapping and the Dayhoff matrix-based method in MEGA6 Software as previously described. 12 Phylogenetic clusters were determined using CTree software. 21 Cloning of bla The bla IMP-31 gene was amplified using the primers IMP-31-fw (AAAA GGATCCGCCCTAAAACAAAGTTAGAA) and IMP-31-rev (TTTTAAGCTTTTATTT GGGGCTGTGAT) using whole-cell DNA from P. aeruginosa NRZ-00156 as a template. The gene was cloned into the pBK-CMV vector using BamHI and HindIII at restriction sites, yielding the recombinant plasmid pMB3007. bla IMP-1 was also cloned into the pBK-CMV vector (pMB3010) to serve as a reference for the MIC studies and the determination of the kinetic parameters. pMB3007 and pMB3010 were transformed into Escherichia coli TOP10 for b-lactamase expression.
Purification of IMP-31 and IMP-1 IMP-31-and IMP-1-expressing E. coli TOP10 cells were grown in 4 L of LB medium at 378C for 18 h and harvested by centrifugation. Cell pellets were resuspended in buffer H (50 mM HEPES, 50 mM ZnSO 4 , pH 7.5) and disrupted by sonication. The lysates were cleared by centrifugation (48 400 g, 30 min, 48C), filtered through a Filtropur S 0.2 mM filter (Sarstedt, Nü mbrecht, Germany) and desalted using a HiPrep 26/10 desalting column (GE Healthcare, Uppsala, Sweden) equilibrated with buffer H. The samples were loaded onto a 5 mL HiTrap SP HP ion exchange column (GE Healthcare, Uppsala, Sweden) at a flow rate of 2 mL/min, previously equilibrated with buffer H. The bound proteins were eluted using a linear NaCl gradient (0 to 1 M). Fractions containing high amounts of protein were loaded onto a HiPrep 16/60 S-200 HR gel filtration column (GE Healthcare, Uppsala, Sweden) equilibrated with buffer H supplemented with 0.15 M NaCl at a flow rate of 0.8 mL/min. b-Lactamase-containing fractions were identified by nitrocefin hydrolysis, pooled, immediately frozen in liquid nitrogen and stored at 2808C. Using this procedure, IMP-31 and IMP-1 were purified to near homogeneity with a purity of .95% as estimated and quantified by SDS-PAGE (data not shown).
Determination of kinetic parameters
The hydrolysis of the b-lactam antibiotics was monitored by measuring the absorbance changes resulting from opening of the b-lactam ring. All measurements were performed at 258C in buffer H under the experimental conditions previously reported 22 -24 using an Eppendorf BioSpectrometer (Eppendorf, Hamburg, Germany). The kinetic parameters k cat and K M were determined using non-linear regression under initial rate conditions using the Michaelis-Menten equation with three independent enzyme preparations.
Nucleotide sequence accession number
The nucleotide sequence of bla IMP-31 has been submitted to the EMBL/ GenBank database and was assigned the accession number KF148593.
Results

Susceptibility testing and MLST determination
According to EUCAST criteria, 25 the P. aeruginosa isolate NRZ-00156 was resistant to imipenem, doripenem and meropenem (MICs .32 mg/L) as well as to piperacillin (96 mg/L) and piperacillin/tazobactam (64 mg/L). It also was resistant to cefepime (128 mg/L) and ceftazidime (.256 mg/L). Regarding the non-b-lactam antibiotics, the isolate was resistant to gentamicin, tobramycin, amikacin (.256 mg/L), ciprofloxacin and levofloxacin (.32 mg/L). The isolate was susceptible to colistin with an MIC of 1.5 mg/L and had intermediate susceptibility to aztreonam with an MIC of 8 mg/L. MBL production was indicated by the performance of the MBL Etest Imipenem, the EDTA-CDT and the EDTA bioassay (data not shown). In the MBL Etest, the MIC of imipenem was 32 mg/L while the MIC of imipenem EDTA was 1.0 mg/L. The oprD gene of P. aeruginosa NRZ-00156 was sequenced, which revealed a premature stop codon resulting in a C-terminal shortening of the OprD protein by 99 amino acids.
The P. aeruginosa isolate NRZ-00156 expressed the allelic profile ST235. eBURST analysis using all the available P. aeruginosa MLST profiles (http://pubmlst.org/paeruginosa/) showed that ST235 belonged to the international clonal complex CC235.
Genetic analysis of bla IMP-31 and gene transfer experiments
Using the consensus primers IMP-A and IMP-B, 14 an internal 587 bp bla IMP gene fragment was amplified. PCRs for other tested MBL genes were negative. As it is known that bla IMP genes are often associated with bla OXA genes within integron structures, 5 combinations of primers for the IMP and OXA genes and Pfennigwerth et al.
conserved class I integron regions yielded PCR products that covered the whole bla IMP ORF (738 bp) that encoded for a 245 amino acid protein. The sequence revealed several base substitutions compared with other known IMP gene variants and the new allele was assigned as bla IMP-31 by the Lahey Clinic b-lactamase database (http://www.lahey.org/studies/). With PCRs and genome walking, 4.8 kbp of the genomic environment of the bla IMP-31 gene was identified. Sequence analysis showed that the bla IMP-31 gene was part of a disrupted class I integron as the first gene cassette under the control of the hybrid PcH2 promoter and an inactive P2 promoter, followed by an attI site. The bla IMP-31 gene was followed by gene cassettes containing bla OXA-35 , aac(6 ′ )-Ib, aac(3)-Ic and aphA15 (Figure 1) . Downstream of the aphA15 gene cassette, the integron was disrupted by a transposon-like structure consisting of a tniC gene, encoding for a site-specific recombinase, and the tnpA gene, encoding for the transposase A protein.
Amino acid sequence analysis
Compared with all 41 publicly available amino acid sequences of IMP-type enzymes, the closest relative to IMP-31 was the recently described IMP-35, with 237/245 (96.7%) amino acid identity 
Phylogenetic analysis
The construction of a phylogenetic tree and cluster analysis with all the available IMP-type carbapenemase amino acid sequences using CTree software clustered the enzymes into Cloning and heterologous expression of bla The bla IMP-31 gene was cloned into the pBK-CMV vector and was constitutively expressed in E. coli TOP10. E. coli TOP10 cells transformed with the pBK-CMV vector and a strain expressing IMP-1 served as a control. Susceptibility testing and MIC determination showed that E. coli TOP10 producing IMP-31 had elevated MICs of all the tested b-lactams except for aztreonam but showed a very diverse resistance profile (Table 1) . Relative to the control strain carrying the empty pBK-CMV vector, increases in MIC ranged from 128-fold for amoxicillin to 3-fold for piperacillin. The highest MIC increases of cephalosporins were detected for ceftazidime (128-fold), cefotaxime (93-fold) and cefoxitin (64-fold), while resistance to cefuroxime and cefalotin was increased by only 32-fold and 21-fold, respectively. The expression of IMP-31 led to slightly higher MICs of carbapenems, with increases of 31-fold for ertapenem, 12-fold for meropenem and doripenem but only 2-fold for imipenem. In comparison with the MICs determined for E. coli TOP10 producing IMP-1, bla IMP-31 -expressing bacteria showed generally lower MICs of all the tested b-lactam antibiotics ( Table 1 ). The expression of IMP-31 had no effect on the MIC of aztreonam. Pfennigwerth et al. , resulting from either low turnover rates or low substrate affinity. The lowest K M values were detected for meropenem (2 mM) and ertapenem (3 mM) while, interestingly, the K M value for imipenem was 30 mM, resulting in a lower affinity. Like IMP-1, IMP-31 was not able to hydrolyse aztreonam.
Enzyme kinetics
Discussion
IMP-type carbapenemases show a continuous worldwide spread among clinical P. aeruginosa strains.
bla IMP genes were first described in Japan and other Asian countries and have been increasingly detected in European countries. 5, 8, 12, 26 To date, 50 IMP-type enzymes have been assigned (http://www.lahey.org/studies/), showing a high diversity regarding their amino acid sequences, with differences of up to 21.8%. In this study, we detected a new IMP variant, IMP-31, which was the most divergent IMP-type enzyme relative to IMP-1.
The amino acid sequence revealed many substitutions compared with other IMP-type enzymes that have publicly available sequences, with only the recently described IMP-35 having an identity of higher than 85%. IMP-31 was 96.7% identical to IMP-35 as its closest relative, but it showed major differences regarding the C-terminal sequence. Unlike most other IMP variants that consist of 246 amino acid residues, IMP-31 was a 245 amino acid protein, shortened by one C-terminal residue. For most IMP-type enzymes, the C-terminus is formed by a KKPSXPSN motif, with the first two lysine residues being conserved in all known IMP variants. For IMP-31, the C-terminal sequence was KNHHSPK, making the C-terminus of the enzyme the most divergent compared with all other IMP-type MBLs. As with most other MBL genes, the bla IMP-31 gene was part of a class I integron and 
Description of IMP-31
showed the same genetic environment as bla IMP-35 regarding the next two gene cassettes of the integron, implying the close relationship of these alleles. However, the sequence downstream of the aac(6 ′ )-Ib gene showed major differences, with two additional resistance genes, aac(3)-Ic and aphA15. In addition, the integron was disrupted by the transposon-associated genes tniC and tnpA, encoding a recombinase of the invertase/resolvase family 27 and transposase A. This suggests a possible transposon-mediated mobilization of bla IMP-31 , as has been shown for other MBLs like VIM-1. 28 As the sequence obtained by PCR and genome walking covered only a part of the transposon structure, it was not possible to determine the type of the transposon or its functionality. In addition, it is not clear whether the transposon-like structure only disrupted the integron or whether the conserved 3 ′ -CS end has been deleted and replaced by the transposon elements such as tniC, as has been shown for a VIM-2-carrying integron. 29 The phylogenetic analysis with all available IMP-type enzymes and the clustering into 13 groups underlined the growing evolutionary complexity of the IMP family. The phylogenetic tree showed IMP-31 to be a member of a new phylogenetic cluster that consists only of IMP-31 and IMP-35. Regarding their amino acid sequences, these two enzymes show distinct differences to all other publicly available IMP-type enzymes, with homologies of only 86.6% (IMP-35) and 84.1% (IMP-31) to their next relatives apart from each other. With an evolutionary distance to a putative common ancestor even greater than that to IMP-35, IMP-31 further illustrates the immense diversity of IMP-type carbapenemases.
The P. aeruginosa isolate NRZ-00156 expressed the allelic profile ST235, which has frequently been reported to be a carrier of different carbapenemases, e.g. IMP-6, VIM-2, GES-6 or PER-1.
30 -33 ST235 belongs to the clonal complex CC235, which has been reported in the context of the production of several MBLs and ESBLs in European countries. 26,34 -36 The discovery of IMP-31 in P. aeruginosa NRZ-00156 further underlines the spread of carbapenemases in clinical P. aeruginosa strains.
IMP-31 and IMP-35 were found in isolates from adjacent geographical regions. This indicates the establishment of a new IMP cluster in Western Europe, which is expected to spread further. With a GC content of 39%, it is very clear that all the IMP variants have been introduced into the P. aeruginosa species, which has a GC content of 66%, but the source of these genes is still unknown. Additionally, all the bla IMP genes have been found within integron structures, most of them located on mobile elements. 5 It can be assumed that IMP genes originate from the intrinsic genes of one or several closely related environmental bacterial species, although these progenitors are as yet unknown, unlike the progenitors of, for example, CTX-M, OXA-48 or OXA-23. 37 -39 Due to the high diversity of IMP-31 and IMP-35 compared with other variants, it can be speculated that they represent a de novo mobilization from their unknown environmental source rather than an evolutionary diversification from other IMP-type enzymes within P. aeruginosa. This would further imply a danger of the continuing introduction of novel resistance genes into bacterial species of medical importance.
Interestingly, E. coli TOP10 cells heterologously producing IMP-31 had relatively low MICs of carbapenems compared with cells expressing IMP-1. The MICs of all the carbapenems tested and many other b-lactams were only slightly elevated. It was shown for other IMP-type enzymes, e.g. IMP-13 and IMP-18, that a heterologous expression of the enzymes in E. coli led to MICs that were not much higher than for the control strains, and these findings were confirmed by a determination of kinetic parameters, although the enzymes conferred high-level resistance to carbapenems in the clinical isolates. 40 -42 As the P. aeruginosa isolate NRZ-00156 exhibited a mutated oprD gene, it can be assumed that this might have an influence on the MICs of imipenem as the OprD porin selectively allows the influx of imipenem into the cell. 43 However, the major contribution of IMP-31 towards imipenem resistance was demonstrated by the pronounced reversion of imipenem resistance in the presence of a chelating agent, as shown by the MBL Etest result.
In general, the observed kinetic data for IMP-31 were in good agreement with the MIC data ( Table 1) , showing a generally low catalytic efficiency of IMP-31 towards all the b-lactams tested. As the amino acid substitutions of IMP-31 compared with IMP-1 are spread widely over the enzyme and it is very likely that they lead to changes in the tertiary structure, this could be an explanation for the higher K M values that were observed for IMP-31. On the other hand, the affinity towards penicillin G and piperacillin was higher than for IMP-1, indicating that the substitutions do not lead to an overall lower affinity. As it has been shown that relatively small changes in the catalytic sites can have a great influence on the catalytic behaviour, 44 the generally lower k cat values of IMP-31 could be based upon slight changes in the active site due to the large number of mutations. An alteration in the zinc-binding capacities of IMP-31, however, is unlikely, as the highly conserved zinc-binding sites of the enzyme show no mutations compared with IMP-1 ( Figure 2) . Further structural analysis, including crystallization, has to be performed to definitely identify the reason for the catalytic behaviour of IMP-31.
In conclusion, our findings show that a new IMP-type enzyme cluster has evolved in Western Europe, carried by CC235 P. aeruginosa strains. With two currently described alleles with a similar genetic context, it is possible that this cluster is going to play an important role in nosocomial infections with P. aeruginosa strains with acquired IMP-type enzymes in Germany. Furthermore, the expression of ST235 by the isolate NRZ-00156 is an indicator that ST235 is continuously spreading in European hospitals and is playing an important role as a carrier of acquired carbapenemases.
